On the other hand, another class of drugs initially proposed for the management of type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP1-RA), has demonstrated significant benefits in patients with excess body weight or obesity and HFpEF [27]. Here, GLP1R is linked to obesity disorder.